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Abstract
To more closely understand the mechanisms of how BCG vaccination confers immunity would help to rationally design
improved tuberculosis vaccines that are urgently required. Given the established central role of CD4 T cells in BCG induced
immunity, we sought to characterise the generation of memory CD4 T cell responses to BCG vaccination and M. bovis
infection in a murine challenge model. We demonstrate that a single systemic BCG vaccination induces distinct systemic
and mucosal populations of T effector memory (TEM) cells in vaccinated mice. These CD4
+CD44
hiCD62L
loCD27
2 T cells
concomitantly produce IFN-c and TNF-a, or IFN-c, IL-2 and TNF-a and have a higher cytokine median fluorescence intensity
MFI or ‘quality of response’ than single cytokine producing cells. These cells are maintained for long periods (.16 months)
in BCG protected mice, maintaining a vaccine–specific functionality. Following virulent mycobacterial challenge, these cells
underwent significant expansion in the lungs and are, therefore, strongly associated with protection against M. bovis
challenge. Our data demonstrate that a persistent mucosal population of TEM cells can be induced by parenteral
immunization, a feature only previously associated with mucosal immunization routes; and that these multifunctional TEM
cells are strongly associated with protection. We propose that these cells mediate protective immunity, and that vaccines
designed to increase the number of relevant antigen-specific TEM in the lung may represent a new generation of TB
vaccines.
Citation: Kaveh DA, Bachy VS, Hewinson RG, Hogarth PJ (2011) Systemic BCG Immunization Induces Persistent Lung Mucosal Multifunctional CD4 TEM Cells which
Expand Following Virulent Mycobacterial Challenge. PLoS ONE 6(6): e21566. doi:10.1371/journal.pone.0021566
Editor: Ludovic Tailleux, Institut Pasteur, France
Received April 15, 2011; Accepted June 2, 2011; Published June 24, 2011
Copyright:  2011 Kaveh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Department for Environment, Food and Rural Affairs, United Kingdom (www.defra.gov.uk). The funders had no role
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: philip.hogarth@ahvla.gsi.gov.uk
Introduction
Tuberculosis (TB) caused by infection with Mycobacterium
tuberculosis or Mycobacterium bovis remains one of the most important
infectious diseases of man and animals respectively, and continues
to inflict a huge cost in humans and animals in both health and
financial terms [1].
At present the only available vaccine against TB is M. bovis
bacille Calmette-Gue ´rin (BCG) which demonstrates variable
efficacy in humans and cattle [2,3]. In particular, BCG induces
effective protection against childhood disseminated TB and
tuberculous meningitis, but poor protection against pulmonary
TB in adolescents and adults [4]. Despite this inconsistent
performance, BCG remains the most widely used human vaccine
in the world and due to its partial efficacy and proven safety
record, is unlikely to be withdrawn. Hence, a great deal of research
effort is targeted toward improving the efficacy of BCG by a
number of approaches; prominent among which is boosting BCG
with heterologous vaccines [5].
A deeper understanding of the T cell mechanisms underpinning
the immunity induced by BCG vaccination would help to identify
immune correlates of protection. This would facilitate and
accelerate the rational design of improved replacement, or adjunct
tuberculosis vaccines.
BCG induced protection is dominated by antigen-specific CD4
T cells with a lesser and as yet poorly defined contribution by
CD8 T cells. IFN-c is essential and combined with TNF-a
production considered to play a central role in protection [6].
Cryptically, measurement of circulating antigen-specific CD4 T
cell production of these cytokines fail to offer reliable a correlate
of protection in many studies [7,8]; whilst they do correlate in
others [9,10,11] reviewed by Goldsack & Kirman [12]. These
data then indicate that whilst CD4 T cell generated IFN-c
production is an essential component of the protective response; it
does not effectively describe all of the mechanisms acting toward
successful protective immune responses. This is further demon-
strated by studies in which, despite increasing the frequency of
IFN-c producing CD4 T cells protective immunity was not
increased [13,14].
The recent identification and description of multifunctional T
cells may represent another major essential component in BCG
induced protection. Multifunctional CD8 T cells associate with
non-progressors in HIV infection [15], multifunctional CD4 and
CD8 T cells characterise protective immunity in the lungs of
influenza infected mice (reviewed by Kohlmeier and Woodland,
[16]). Multifunctional CD4 T cells have been identified, and
represent a correlate of protection in a murine leishmania
vaccination/challenge model [17]. More recently, they have been
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in described in M. tuberculosis infection and vaccination models in
mice [18,19], non-human primates (NHP) [20] and human
vaccination studies [17,21]. These studies show a distinct correla-
tion between the frequencies of these cells and the expression of
protective immunity. Despite these encouraging results, however,
formal demonstration that these cells mediate protection during
vaccination against tuberculosis remains elusive. In studies of
human infection however, the role of multifunctional T cells
remains more cryptic and they may represent a correlation with
active disease [22,23,24].
We sought to investigate the role of these cell types in our
previously established murine BCG vaccination and M. bovis
challenge model [25]. Importantly, we were able to demonstrate
that intradermal, non-mucosal, BCG immunization was able to
induce a persistent, long lived population of multifunctional CD4
+
cells in the lungs which preferentially expand following challenge.
These cells exhibited a complex effector memory (TEM) phenotype
and associate with BCG induced protection against mucosal
tuberculosis challenge.
Our study is the first to describe significant expansion of BCG-
specific lung resident multifunctional CD4 TEM cells during the
protective response to virulent mycobacterial challenge. We
propose that these cells mediate protective immunity, and that
vaccines designed to increase the number of relevant antigen-
specific TEM in the lung may represent a new generation of TB
vaccines.
Results
BCG immunization induces significant protection in
spleen and lung against M. bovis challenge
To establish the efficacy of BCG to induce protection against M.
bovis intranasal (i.n.) challenge, two separate duration experiments
were undertaken. First, groups of BALB/c mice were BCG or
sham immunized by the intradermal route (i.d.) six weeks prior to
i.n. challenge with M. bovis. Upon determination of bacterial load
four weeks after challenge, BCG immunised groups displayed
highly significant protection in the spleen ,1.5 log10 (r,0.001)
and lungs ,2 log10 (r,0.01) (Table 1
A, representative data of 1 of
4 separate experiments).
Second, groups of mice were BCG or sham immunized as
described at week 0 or BCG immunized at week 48 and all
challenged at week 54. Again, BCG immunised groups displayed
highly significant protection in the spleen and lungs (r,0.001)
Table 1
B.
BCG induces a higher frequency of IFN-c producing CD4
T cells in the lungs than spleen
Given the established importance for IFN-c producing CD4 T
cells in protection against tuberculosis infection, we assessed the
frequency of antigen-specific IFN-c cells by ELISPOT during the
course of M. bovis infection in BCG or sham immunised animals.
In the spleen (Figure 1A), immunization induced a mean
frequency of 252 Spot Forming Units (SFU)/million cells
compared to controls (8 SFU, r,0.01). Following challenge this
increased transiently for the first seven days (383 SFU day 7,
r,0.05 c.f. controls) and then declined to day 14. In the lung,
however (Figure 1B), the pre-challenge frequency of IFN-c
producing cells in vaccinated mice was significantly higher than
the spleen (2220 SFU/million cells, r,0.05). Following challenge,
the frequency of IFN-c producing cells in the vaccinated lung
continued to increase (max. 9538 SFU) and was significantly
higher than control mice at all time points except day 28. By 28
days post infection there were significant numbers of IFN-c
producing cells in the spleen (356 SFU) and the lungs (6570 SFU)
of control animals, most likely indicating a response to M. bovis
challenge rather than vaccination by this time. The frequency of
IFN-c producing cells was up to 30 fold higher in the lung than
spleen during vaccination/infection, indicating that BCG induced
a preferential mucosal rather than systemic antigen-specific
immune response.
BCG vaccination induces CD44
hi multifunctional CD4 T
cells producing IFN-c, IL-2 and TNF-a
In order to determine the functionality of the responding T cells
induced by BCG vaccination, spleen and lung lymphocytes were
isolated from sham and BCG immunized animals at six weeks post
vaccination. These cells were stimulated with a cocktail of
mycobacterial proteins and subsequently interrogated by intracel-
lular staining (ICS) and 9 colour flow cytometric analysis. Spleen
cells derived from BCG vaccinated animals exhibited cytokine
production by cells of a CD4
+CD44
hi phenotype at a significantly
greater frequency than cells derived from controls (IFN-c, 0.57 vs.
0.03%; IL-2, 0.65 vs. 0.09%; TNF-a, 0.73 vs. 0.06%). CD4
+ lung
derived cells showed an equivalent frequency of cytokine
producing cells (IFN-c, 0.75 vs. 0.04%; IL-2, 0.75 vs. 0.05%;
TNF-a, 4.41 vs. 0.33%) (Figure 2).
Further staining and analysis of these cytokine producing spleen
and lung cells by ICS revealed the majority of them to be
multifunctional, with 0.49% of CD4
+ spleen cells and 0.62% of
CD4
+ lung cells being IFN-c
+IL-2
+TNF-a
+ (Figure 2).
Table 1. BCG induced protection in the spleen and lungs of M. bovis challenged mice.
Spleen Lung
Log10 CFU S.E. Log10 protection Log10 CFU S.E. Log10 protection
Experiment 1
a
Control 4.86 0.17 - 6.95 0.30 -
BCG 3.38 0.10 1.48 *** 5.07 0.14 1.88 **
Experiment 2
b
Control 4.16 0.23 - 6.18 0.10 -
BCG 6 wks 3.04 0.21 1.12** 5.07 0.11 1.11***
BCG 1 year 2.62 0.10 1.55*** 4.81 0.18 1.37***
aExperiment 1, mice immunized 6 weeks prior to challenge: un-paired student’s two-sided t - test ** r,0.01, *** r,0.001 (n=5).
bExperiment 2, mice immunized six weeks or one year prior to challenge: one-way ANOVA with Bonferroni post-test * r,0.05, ** r,0.01, *** r,0.001 (n=8).
doi:10.1371/journal.pone.0021566.t001
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quality of response than single producers
Median Fluorescence Intensity (MFI) of cells analysed by ICS
is a direct correlate of the physical amount of cytokine produced
per cell. We measured the individual IFN-c, IL-2 and TNF-a
MFI of spleen cells at six weeks post vaccination in subsets of
CD4
+CD44
hi T cells producing the 7 potential cytokine
combinations (Figure 3). For IFN-c, the amount of cytokine
produced increased with the number of cytokines being
concomitantly expressed, from an IFN-c MFI of 152 for IFN-c
single positive cells, to an MFI of 1063 for triple positive cells, an
increase of 7 fold. For TNF-a production displayed a similar
correlation with a TNF-a MFI of 100 for TNF-a single positive
cells and an MFI of 215 for triple positive cells, a 2 fold increase.
For IL-2, the MFI was highest in single positive cells (149),
although these were not significantly greater than the triple
positive cells (123). It should be noted that the overall lower MFI
exhibited by IL-2 producing cells may lower the sensitivity of
these measurements.
Thus, triple cytokine producing cells expressed a higher quality
of response in terms of the amount of IFN-c and TNF-a produced
per cell.
Multifunctional CD4 T cells express a
CD44
hiCD62L
loCCR7
2CD27
2 Phenotype
In order to establish whether the multifunctional cells induced
by BCG immunization expressed a memory or effector type
phenotype, we further investigated the surface phenotype of these
cytokine producing cells in spleen (Figure 4) and lungs (data not
shown) six weeks following vaccination. Gating on total CD4
+ cells
showed that 16% of these cells expressed a CD44
hiCD62
lo TEM
phenotype and gating on the cytokine producing cells demon-
strated that 95% of IFN-c
+, 88% of IL-2
+ and 89% of TNF-a
+
cells reside within this phenotype (Figure 4A). Staining for CCR7
expression revealed a negative phenotype, indicating that these
cells were not central memory (data not shown). Further
phenotyping revealed that whereas 9% of total CD4
+ cells were
CD44
hi and negative for CD27; 98% of IFN-c
+, 83% of IL-2
+ and
91% of TNF-a
+ cells displayed this surface phenotype (Figure 4B).
The loss of CD27 appears to indicate that these cells have
undergone terminal differentiation but still express memory
markers. Together these data show that the cytokine producing
cells express a CD4
+CD44
hiCD62L
loCCR7
2CD27
2 effector
memory phenotype.
IFN-c producing cells in the lung reside in the lung
interstitium compartment
In order to determine which compartment of the lung the IFN-c
producing cells reside in, lung interstitial cells and bronchoalveolar
lavage (BAL) cells were isolated from BCG immunised mice. The
frequency of antigen-specific IFN-c cells in each cell population
was assessed by ELISPOT.
Whole lung lymphocytes and lung interstitial cells prepared
from BAL depleted lungs contained a similar frequency of IFN-c
secreting cells (1700 & 1500 SFU per lung), whereas BAL derived
lymphocytes contained very few IFN-c secreting cells (22 SFU per
lung) (Figure 5). These results clearly demonstrate that the IFN-c
producing cells in the lungs induced by BCG vaccination reside
within the lung interstitial cells and not the bronchoalveolar
compartment.
Multifunctional cells in the spleen express a lung homing
phenotype
In order to investigate whether the antigen specific T cells
identified in the lung are derived from the spleen; spleen and lung
cells isolated from BCG and sham immunised mice were stained
for the potential lung homing surface markers a1 integrin
(CD49a), a4-integrin (CD49d), b1-integrin (CD29), CD11a and
CXCR3.
Plots are shown for IFN-c
+ T cells (as we have shown the
majority of IFN-c
+ cells are multifunctional for IL-2
+ and TNF-
a
+), to overcome the limitations of low numbers of triple positive T
cells recovered from the lungs in unchallenged mice (Figure 6).
CD4
+CD44
hiIFN-c
+ spleen cells were negative for the a1
integrin (CD49a) (data not shown), but 30% of IFN-c
+ cells were
positive for a4b1 integrin heterodimer(Figure 6A) vs. only 14% of
total CD4
+ cells (6B). In the lung, this was reduced to 12% IFN-c
+
(6C) vs. 3% total CD4
+ (6D).
80% of spleen IFN-c
+ cells co-expressed CD11a and b1
(Figure 6E) vs 26% total CD4
+ (6F). In the lung this was reduced
to 20% (6G) and 7% (6H), respectively.
Figure 1. Frequency of IFN-c secreting cells in spleen and lung
from BCG immunized mice following M. bovis challenge.
Lymphocytes of the spleen (A) and lungs (B) from mice (n=5)
immunized six weeks previously with BCG or placebo were isolated
prior to and post challenge with M. bovis. Following re-stimulation with
antigen cocktail, cells were enumerated for IFN-c production by
ELISPOT. Symbols represent mean (6S.E.) spot forming units adjusted
per 10
6 cells. Un-paired student’s two-sided t - test * r,0.05, ** r,0.01.
doi:10.1371/journal.pone.0021566.g001
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+ cells also expressed high levels of
the chemokine receptor CXCR3 (43% (6I) vs. 12% of total CD4
+
(6J)). In the lung the trend for down regulation was maintained
with 22% of IFN-c
+ cells expressing CXCR3 (6K) vs. 7% of total
CD4
+ cells (6L).
Together these data show that BCG induced multifunctional T
cells in the spleen display up-regulated co-expression of the
potential lung homing markers, a4b1 and CD11a, and up-
regulated expression of the chemokine receptor CXCR3, which
can confer lung homing properties to Th1 cells under inflamma-
tory conditions (e.g. M. bovis infection). Conversely, analysis of
these markers in lung derived BCG induced multifunctional T
cells indicates a trend of down regulation, perhaps indicating that
cells resident in the lung no longer need to express these markers.
Vaccination induced, resident multifunctional CD4 T cells
undergo preferential expansion in the lung following M.
bovis intranasal challenge
Six weeks following vaccination, BCG and sham immunized
mice were challenged with 600 CFU virulent M. bovis intranasally
route. Spleen and lung lymphocytes were isolated prior to and 14
days following challenge and the frequencies of antigen-specific
CD4
+ CD44
hi cells exhibiting all seven combinations of IFN-c, IL-
2 and TNF-a production were determined (Figure 7). BCG
Figure 2. BCG induces CD4
+CD44
hi T cells secreting IFN-c, IL-2 & TNF-a. Six weeks following immunization, spleen (B) and lung (C) cells from
BCG or sham control vaccinates were isolated, stimulated and stained by intracellular staining (ICS). Plots were gated on live CD4
+ lymphocytes (A)
and analyzed for all combinations of cytokine productivity. Numbers indicate percentage of CD4
+ cells, data are representative of 1 of 3 independent
experiments.
doi:10.1371/journal.pone.0021566.g002
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spleen and lungs which increased in proportion following
challenge.
In the spleen comprised: 0.11% IFN-c
+IL-2
+TNF-a
+ cells pre-
challenge to 0.25% post-challenge,; 0.06% IFN-c
+TNF-a
+ cells to
0.13%, r,0.05; 0.05% IL-2
+TNF-a
+ cells to 0.16% post-
challenge, r,0.001; and 0.19% TNF-a
+ cells to 0.34%,
r,0.05, pre- and post-challenge, respectively (Figure 7A).
These increases were substantially greater in the lungs following
challenge:
0.1% IFN-c
+IL-2
+TNF-a
+ increases to 3.84%; IFN-c
+TNF-a
+
0.16 to 2.26%; IL-2
+/TNF-a
+ 0.06 to 4.6% and TNF-a
+ 0.38 to
6.01%, r,0.05 (Figure 7B). Multifunctional responses induced by
challenge of naı ¨ve animals were less than induced by BCG
vaccination (Figure 7). CD8 T cell responses in both spleen and
lung were negligible (data not shown). Unless stated, changes form
pre-to post-challenge were not statistically significant (n.s.).
Together these data demonstrate the preferential expansion of
cells expressing two or more cytokines, with the multifunctional
lung lymphocytes exhibiting a mean 38 fold expansion. IFN-c/
TNF-a double positive and IFN-c/IL-2/TNF-a triple positive
cells were the functional phenotypes most strongly associated with
protection. Interestingly, infection induced a substantial expansion
of TNF-a single positive cells and IL-2/TNF-a double positive
cells.
BCG induces a CD4
+CD44
hi multifunctional T cell
response for at least 18 months post vaccination
To assess the longevity of the multifunctional CD4 T cell
response, spleen and lung lymphocytes from BCG immunised
mice were isolated, restimulated with antigen cocktail and
interrogated by ICS at, 1, 6, 12 and 18 months post immunization
(Figure 8). Both the frequency (Figure 8A) and absolute proportion
(Figure 8B) of IFN-c
+IL-2
+TNF-a
+ cells increased over time in
Figure 3. Multifunctional CD4
+CD44
hi T cells produce a better quality of response. Six weeks following BCG immunization, spleen cells
were isolated, stimulated and stained by ICS. The antigen-specific IFN-c, IL-2 and TNF-a Median Fluorescence Intensity (MFI) of all 1
+,2
+ or 3
+ cytokine
secreting subsets of CD4
+CD44
hi cells were determined. Symbols represent the mean IFN-c, IL-2 and TNF-a MFI of the indicated T cell phenotype. Un-
paired student’s two-sided t - test * r,0.05, ** r,0.01 (n=4). Data are representative of 1 of 3 independent experiments.
doi:10.1371/journal.pone.0021566.g003
Figure 4. Multifunctional CD4
+ cells have a CD44
hiCD62L
loCD27
2ve phenotype. Spleen cells isolated from six week BCG immunized mice
were stained for cytokine production by ICS and phenotyped for CD44, CD62L and CD27 expression. Regions represent % of cells exhibiting a
CD4
+CD44
hiCD62L
lo (A) or CD4
+CD44
hiCD27
2 (b) phenotype. Plots are gated on CD4
+ cells and are representative of 1 of 3 independent experiments.
doi:10.1371/journal.pone.0021566.g004
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proportion of double cytokine producers, IFN-c
+TNF-a
+ and
IL-2
+TNF-a
+, (Figure 8B).
There was a clear biphasic nature in the magnitude of the
antigen-specific CD4 T cell response in both the spleen and lung
(Figure 8A). At 12 months post vaccination the frequency of the
CD4
+ multifunctional T cells dropped to the levels observed at 6
weeks post-vaccination, but at 18 months had risen equivalent to
those observed at 6 months. The proportion of multifunctional
responders remained similar at this time (Figure 8B). This was
repeatedly observed in several separate experiments, but the
mechanisms underlying this are unclear at this time, and beyond
the scope of this study.
These data demonstrate that BCG immunization induces a
complex T cell response which persists at least 18 months post
vaccination. We also determined whether BCG vaccine induced
immunity persisted in parallel with multifunctional T cells by
challenging mice 12 months post-vaccination, i.e. at a time of
stable multifunctional T cell responses. As shown in Table 1,
protection at one year remained comparably significant to mice
challenged six weeks following BCG immunization.
Discussion
To more closely understand the T cell mechanisms underlying
BCG vaccination induced immunity would help to identify
immune correlates of protection and facilitate the rational design
of improved replacement or adjunct tuberculosis vaccines. Given
the established central role of CD4 T cells in BCG induced
immunity, we sought to characterise the generation of memory
CD4 T cell responses to BCG vaccination and the response of
these cells during the active expression of protection against
virulent mycobacterial challenge in a murine model.
We demonstrate that a single systemic BCG immunization
induces both systemic and mucosal multifunctional CD4 T cells
with a surface phenotype associated with highly differentiated
effector memory T cells (TEM). These TEM were detectable for at
least 18 months post vaccination, underwent significant expansion
in the lungs following infection and are, therefore, strongly
associated with protection against M. bovis challenge.
Assessing the magnitude and frequency of pivotal cytokines,
such as IFN-c has remained the standard measurement of vaccine
induced T cell memory for many years. It has become clear
recently, however, that these relatively simple ex vivo assays cannot
consistently predict vaccine success or adequately describe the
complexity of the CD4 T cell response to vaccination [6]. Indeed,
these assays must be interpreted with care as it is well documented
that ESAT-6 and PPD stimulated IFN-c correlate with bacterial
load [12,26,27], whilst TB10.3 and TB10.4 induced responses
strongly correlate with protection [9,11]. In the current study, we
have therefore used a defined cocktail of secreted, strongly
antigenic proteins to circumvent this bias toward a single antigen,
or ill defined crude preparation skewing the results.
Recent reports have identified and highlighted the role of
multifunctional T cells in a number of disease and vaccination
models [15,18,19,20,28]. Multifunctional CD4 T cells define a
correlate of protection against Leishmania major [17] and associate
with vaccine induced protection against M. tuberculosis in mice
[18,19,29], non-human primates (NHP) [20] and vaccine induced
responses in humans [21,30,31]. Multifunctional CD8 T cells
associate with HIV non-progressors [15]. Protective immunity in
the lungs of influenza infected mice is also characterized by CD4
and CD8 T cells with a multi-functional phenotype [16]. In
contrast, recent reports correlate M. tuberculosis associated multi-
functional cells with active disease in humans, [22,23,24]. Whether
multifunctional cells represent a non-protective profile in active
human disease or their protective role is mediated by other factors
in this more complex scenario remains to be elucidated.
Our study however, is the first to describe significant expansion
of BCG-specific lung resident multifunctional CD4 TEM cells
during the protective response to virulent mycobacterial challenge.
Supported by the analysis of the cells identified in our study, A
common feature of multifunctional T cells, [17,18,19], is the
ability to produce more cytokine than single positive cells, on a per
cell basis, termed a higher ‘quality’ of response, allowing
concomitant effector function (reviewed in [32]).
There are conflicting reports in the literature as to whether
vaccination induced multifunctional T cells represent a subset of
effector (TEM) or central (TCM) memory T cells. Darrah et al.,
describe Leishmania vaccine multifunctional T cells to predom-
inantly associate with a TEM phenotype [17], whilst Lindestrom et
al., identify tuberculosis subunit vaccine induced multifunctional
cells to be TCM [19], both studies using CCR7 expression as the
defining factor.
Our results suggest that the multifunctional CD4 T cells defined
in this study express a CD44
hiCD62L
loCCR7
2 phenotype, which
in concordance with Darrah et al., [17] we propose to be TEM cells.
Another, recent report supports this conclusion; observing a
predominant T effector (TEff)o rT EM cell phenotype in the lungs
Figure 5. IFN-c producing cells in the lungs reside in the lung
interstitium compartment. Whole lung lymphocytes (without BAL
performed), lung interstitial cells (after BAL performed) and broncho-
alveolar lavage (BAL) cells were isolated from six week BCG immunized
mice and assayed for IFN-c production by ELISPOT. 5610
5 cells were
cultured with antigen cocktail and developed by ELISPOT, photographs
of representative wells (A), bars representing the mean (6S.E.) spot
forming units (SFU) adjusted per lung (B). Representative example of 1
of 3 independent experiments.
doi:10.1371/journal.pone.0021566.g005
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cytokine multifunctionality was not established in that study.
Interestingly; Orme [34] hypothesises that development of TCM
from effector responses are impaired by persisting mycobacteria
following infection or BCG vaccination. This is supported by
published data [35,36,37] and our own recent observations that
parenteral BCG vaccination results in BCG bacilli persisting,
albeit at low bacillary numbers, for at least sixteen months post-
vaccination in spleen and lymph nodes (Kaveh and Hogarth
manuscript in preparation). These observations therefore suggest
that the detection of multifunctional CD4 TEM rather than TCM,
may be due to persistence of antigen in sufficient quantity to
support the maintenance of TEff and TEM cells. In contrast, the
development of TCM responses may be more dependent on the
clearance of BCG and consequently lower antigen availability,
consistent with the hypothesis that TCM cells are generated once
antigen is cleared. Whilst this is a strongly held hypothesis, the
effect of continued BCG derived antigen on the maintenance of
this TEM population needs to be demonstrated experimentally, for
which experiments are underway in our laboratory.
CD27
2 CD4 T cells have been identified as protective against
tuberculosis via IFN-c production, although simultaneous cytokine
Figure 6. Multifunctional cells in the spleen express a lung homing phenotype. Spleen and lung cells isolated from six week BCG
immunized mice were stained for cytokine production by ICS and phenotyped for homing markers. Plots are gated on CD4
+ (or IFN-c
+CD4
+) cells and
regions represent % these cells exhibiting a positive homing marker phenotype for: a4-integrin (CD49d) and b1-integrin (CD29) by IFN-c
+CD4
+ cells in
the spleen (A) and the lung (C) or by the total CD4
+ cell population in the spleen (B) and lung (D); CD11a by IFN-c
+CD4
+ cells in the spleen (E) and the
lung (G) or by the total CD4
+ cell population in the spleen (F) and lung (H); and CXCR3 by IFN-c
+CD4
+ cells in the spleen (I) and the lung (K) or by the
total CD4
+ cell population in the spleen (J) and lung (L). Plots are representative of 1 of 3 independent experiments.
doi:10.1371/journal.pone.0021566.g006
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of CD27 is associated with the development of effector function
[38,40,41,42]. Whilst CD27
2 CD4 T cells are considered short
lived terminally differentiated effector (TEFF or TEM) cells in some
experimental systems [39,43], the concomitant production of IL-2
and IFN-c by these cells seen here, infers memory as well as
effector function as suggested by others [41]. We, therefore,
propose that the multifunctional CD44
hiCD62L
loCCR7
2CD27
2
CD4 T cells we observe represent a population of highly
differentiated, but not terminally differentiated TEM cells. The
ability of these TEM to persist in the lung for at least eighteen
months post vaccination is striking. This may reflect persistence of
antigen providing prolonged low level stimulation promoting
survival as discussed; or perhaps, continuing priming by persistent
BCG providing recent immigrant TEM to the mucosal T cell pool.
As mentioned, current experiments investigating the effect of BCG
persistence are aimed at clarifying the mechanism following BCG
vaccination.
In the current study, the antigen specific CD4 T cells most
strongly associated with BCG vaccination were of an IFN-c
+IL-
2
+TNF-a
+ and IFN-c
+ TNF-a
+ phenotype and were seen to
expand on an M. bovis challenge. However, the expansion of the
TNF-a
+ and IL-2
+TNF-a
+ cells may also reflect an important role
during protection. In support of these findings, the former two cell
subsets dominated in other studies of leishmania and BCG vaccine
responses [17,18,19,44]. These include studies evaluating protec-
tive subunit TB vaccines, which additionally induced a substantial
population of the IL-2
+TNF-a
+ subset. A greater importance of
the IFN-c/IL-2/TNF-a triple producers may be suggested by our
data revealing a decrease in the proportional representation of the
IFN-c/TNF-a double producers from 6 months post vaccination
onwards. With cohorts of mice M. bovis challenged at 6 weeks or
12 months post vaccination displaying comparative log10 protec-
tion, the single common protective correlate was a high frequency
of BCG specific IFN-c/IL-2/TNF-a triple producing CD4 T cells.
A recent study by Mu et al. [45] using intranasal vaccination of
mice with a protective adenovirus vaccine demonstrated that
persistent antigen-specific CD8 T cells also displayed an activated
TEM phenotype. Further, these cells are self-renewable in an
antigen-dependent manner, and could be maintained independent
of peripheral T cell supply. It is therefore plausible that the
expansion of multifunctional TEFF/TEM cells following M. bovis
infection in the present study is due to expansion of cells resident
in the lung at the time of infection. However, we can not rule out
that these cells are ingressing from draining lymph nodes or other
peripheral lymphatic tissues following infection, as we observed
identical T cell populations in the spleen.
We, therefore, investigated a number of potential lung homing
markers including the heterodimer a4b1, the activation marker
CD11a and the chemokine receptor CXCR3. The expression of
a4b1 has been described to localize M. tuberculosis-specific Th1
responses in human lungs [46], promote lung-homing of CD4 T
cells in asthmatic patients [47], whilst blocking a4 integrin and
VCAM-1 significantly inhibits the migration of memory T cells to
bronchiolar associated lymphoid tissue (BALT) in mice [48]. The
integrin CD11a is required for host resistance following infection
with M. tuberculosis. In CD11a
2/2 mice, antigen-specific T cell
priming is delayed and T cell trafficking to the lung is impaired
[49]. A deficiency in CXCR3, the receptor for the IFN-c inducible
T cell chemokines CXCL9, CXCL10 and CXCL11, impairs the
trafficking of adoptively transferred Th1 cells to the lung in wild-
type mice [50]. Expression of CXCR3 ligands are abundant in
granulomas of M. tuberculosis infected Macaques and promote the
recruitment of CXCR3
+ cells [51]. The expression of CXCL9,
CXCL10, and CXCL11 were also highly increased in BCG-
vaccinated mice after M. tuberculosis infection [52].
Together, our data showing the up-regulation of these homing
markers on a significant proportion of the BCG induced spleen
derived multifunctional cells, infers these may be a source of the
cells detected in the lung. The down-regulation of these markers
on the lung derived cells suggests their expression may no longer
be required once the cells are resident in the lung.
Interestingly, preliminary data from our laboratory indicates
that sorted spleen derived CD44
hi CD4 T cells home and
accumulate in the lungs but not spleen following adoptive transfer
and M. bovis challenge. This confirms that these cells possess lung
homing capability under inflammatory conditions (data not
shown).
The study by Mu et al. and earlier reports by this group is also
interesting in that they correlated protection after intranasal viral
vaccination with the presence of antigen-specific CD8 T cells in the
airway lumen and not in the lung interstitium. In contrast we found
only minor CD8 responses, and the described multifunctional CD4
T cell populations in ourstudy weremainly locatedin the interstitial
tissue of the lung rather than the lumen. The differences could be
due to the nature of the adenoviral vector system favouring CD8
responses and the intranasal challenge route, respectively.
Figure 7. Vaccination induced resident multifunctional CD4
+
cells in the spleen and lungs undergo expansion following
challenge. The frequency of multifunctional CD4
+CD44
hi cells was
determined in the spleen (A) and lungs (B) of control mice, BCG
immunized mice, and control and BCG immunized mice fourteen days
post challenge. Bars represent mean (6SE) % frequency of cells of
indicated T cell phenotype as a % of total CD4
+ cells. Un-paired
student’s two-sided t - test * r,0.05, ** r,0.01, *** r,0.001.
doi:10.1371/journal.pone.0021566.g007
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CD4 T cells correlate with protective immunity, and indeed could
constitute the protective T cell sub-population. This is clearly
supported by our observation of a dramatic expansion of these
cells following mycobacterial challenge. However, we acknowledge
that this hypothesis will need to be confirmed in further studies
Figure 8. BCG induced CD4
+CD44
hi multifunctional T cells persist at least 18 months post vaccination. The frequencies of antigen-
specific CD4
+CD44
hi cells exhibiting all functional phenotypes of IFN-c, IL-2 and TNF-a production were determined by ICS in the spleen (black bars)
and lungs (white bars) of BCG immunized mice up to 18 months post immunization (A). Bars represent mean (6SE) frequency of these cells as a % of
total CD4
+ cells minus the responses of age matched sham control mice, n=2–8. Pie charts (B) represent the proportion of these cells exhibiting a 1
+,
2
+ or 3
+ cytokine production phenotype, at the corresponding time points.
doi:10.1371/journal.pone.0021566.g008
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which are underway.
The preferential induction of a mucosal response by a non-
mucosally administered BCG demonstrated in the present study
was striking. Other reports of a strong lung response to
immunization involve intranasal vaccine delivery [18,53,54].
These results thus demonstrate the potential of systemic
vaccination to induce long lasting immunity and resident specific
T cells in the lung. This is an encouraging observation and could
explain why intranasal viral subunit boosting is effective in
boosting systemically primed BCG responses.
Our data demonstrate that a persistent mucosal population of
TEM cells can be induced by parenteral immunization, a feature
only previously associated with mucosal immunization routes; and
that these multifunctional TEM cells are strongly associated with
protection. We propose that these cells mediate protective
immunity, and that vaccines designed to increase the number of
relevant antigen-specific TEM in the lung may represent a new
generation of TB vaccines.
In conclusion, the major observation in our study is that
multifunctional memory T cells can be induced and maintained in
the lung for a long period of time after systemic BCG vaccination
without the need to use a mucosal route.
Materials and Methods
Ethics
All animal work was carried out in accordance with the UK
Animal (Scientific Procedures) Act 1986; under appropriate
personal and project licences. The study protocol was approved
by the AHVLA Animal Use Ethics Committee (UK Home Office
PCD number 70/6905).
Animals
Female BALB/c mice were obtained from SPF facilities at
Charles River UK Ltd and used at 8 weeks of age. All animals
were housed in appropriate BSL3 containment facilities at
AHVLA.
Mycobacteria
The vaccination strain used was the human vaccine M. bovis
BCG Danish 1331, prepared as per manufacturer’s instructions
(SSI, Denmark).
Mycobacterium bovis isolate AF2122/97 was grown to mid-log
phase in Middlebrook 7H9 broth (Gibco, UK) supplemented with
4.16 g/L pyruvic acid, 10% v/v OADC and 0.05% v/v Tween 80
(all Sigma, UK), subsequently frozen at 280uC, and used for all
virulent challenges.
Mycobacterial antigens
M7, a pool of 7 secreted, immunogenic recombinant mycobac-
terial proteins (Rv1886c, Rv0251, Rv0287, Rv0288, Rv3019c,
Rv3763, Rv3804c) was used for antigen-specific stimulation.
Rv1886, Rv3019c Rv3804c and Rv3763 were purchased from
Lionex GmbH, Germany. Rv0251, Rv0287 and Rv0288 were
purchased from Proteix s.r.o., Czech Republic.
Immunization and mycobacterial challenge
Mice were immunized with a single intradermal (i.d.) injection
of 2610
5 CFU of BCG. Control mice were immunized with PBS.
Six weeks following immunization, mice were challenged intrana-
sally with approx. 600 CFU of virulent M. bovis as previously
described (Logan et al, 2008). Four weeks after challenge, the mice
were euthanized and the lungs and spleens removed and
homogenised. These homogenates were serially diluted and plated
out on modified Middlebrook 7H11 agar media [55]. Bacterial
colonies were enumerated four weeks later following incubation at
37uC. For protection longevity study, mice were immunized with
BCG or PBS at week zero or week forty eight. At week fifty four all
mice were challenged with approx. 600 CFU of virulent M. bovis.
Four weeks after challenge bacterial load in spleen and lungs were
assessed as previously. For long term BCG induced immunology,
spleen and lungs were harvested as described at up to eighteen
months post vaccination.
Cell isolations and stimulations
To isolate cells from different organs, the following procedure
was undertaken in sequence.
Bronchoalveolar lavage (BAL) cells were isolated as described
previously [54]. Briefly, the lungs were removed, catheterised and
flushed five times with HBSS. BAL derived cells were
resuspended at 5610
6/ml for assays. The right ventricle was
then perfused with ice cold HBSS prior to aseptic removal of the
lungs and spleen.
Spleen cells were prepared by passage through a 40 mm cell
strainer into DMEM (Sigma, UK) supplemented with 10% v/v
FCS and antibiotics (100 U/ml penicillin and 100 mg/ml
streptomycin) (Gibco). Following washing at 300 g for 8 min,
cells were re-suspended at 5610
6/ml for assays.
Lung interstitial cells were isolated by finely minced the lungs,
and re-suspended into 25 ml digestion media (supplemented
DMEM plus 150 U/ml Collagenase I (Gibco) and 10 U/ml
DNAse II (Sigma). Following stirring (,200 rpm) at 37uC for
1 hour, lung cells were passed through a 40 mm cell strainer,
washed & re-suspended at 5610
6/ml (5610
5 post challenge) for
assays.
Cells were cultured with a pool of 7 recombinant antigens as
described, each antigen at a final concentration of 2 mg/ml for all
assays.
ELISPOT
5610
5 cells (or 5610
4 lung cells post challenge) were incubated
in duplicate in 96 well filter plates (MSIPS4510 Millipore, Ireland)
with or without antigen for 16 hours and the frequency of IFN-c
secretors detected by ELISPOT (Mabtech, Sweden), as per
manufacturer’s instructions
Flow cytometry
Cells isolated from spleen or lungs were stimulated with
recombinant antigen pool and 1 mg/ml anti-CD28 (BD
Biosciences, UK) for 2 hours at 37uC/5% CO2.B r e f e l d i nA
(Sigma) was added at 10 mg/ml and cells cultured for a further
16 hours. Cells were washed (300 g/5 mins) and surface stained
with CD27 - PE, CD4 - PE-TexasRed (Invitrogen, USA) or –
APC-H7, CD44 - PE-Cy5 or - Qdot705 (Invitrogen, USA),
C D 6 2 L–b i o t i n ,-F I T C ,–P Eo r–P E - T e x a s R e d( I n v i t r o g e n ) ,
CD8 - APC-Cy7, Violet fixable deadc e l ls t a i na n ds t r e p t a v i d i n-
Pacific Orange (both Invitrogen). Subsequently the cells were
washed, treated with BD Biosciences Cytofix/Cytoperm ac-
cording to manufacturer’s instructions and stained intracellu-
larly with IFN-c -A P C ,I L - 2–F I T C ,-P Eo r-P E - C y 7a n d
TNF-a - PE-Cy7 or - FITC (eBioscience, USA). All antibody
conjugates were purchase from BD Bioscences except where
stated). Following washing, cells were analysed using a CyAn
ADP analyser and Summit software (Beckman Coulter, USA).
All analyses and plots were gated on a minimum of 100 000 live
lymphocytes.
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All data was analysed using GraphPad Instat 3 statistical
package (GraphPad, USA). Mycobacterial counts were log10
transformed and analyzed using the unpaired Student’s t-test (Exp.
1), or ANOVA with Bonferroni post-test (Exp. 2). ELISPOT data
were analysed using the unpaired Student’s t-test with Welch
correction.
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